StockMarketWire.com - Hikma Pharmaceuticals and Gedeon Richter announced the signing of an exclusive license agreement to sell the latter's antipsychotic in certain Middle East and North African markets.

Under the terms of the agreement, Richter would be responsible for product supply and Hikma would proceed with the registration and commercialisation of the product in Bahrain, Egypt, Jordan, Iraq, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Sudan, Syria and United Arab Emirates.

Richter would receive from Hikma an upfront payment and would also be entitled to sales related milestone payments on achievement of certain targets.


At 9:01am: [LON:HIK] Hikma Pharmaceuticals PLC share price was +24.5p at 1829p



Story provided by StockMarketWire.com